<DOC>
	<DOCNO>NCT03049774</DOCNO>
	<brief_summary>The aim retrospective study review describe safety efficacy recombinant human interleukin-11 ( I ) ( Baijieyi ) , use information already record 20 medical record , The time period include May 8th 2008 december 31st 2016 .</brief_summary>
	<brief_title>A Study Recombinant Human Interleukin-11 ( I ) ( Baijieyi ) Prevention Treatment Chemotherapy-induced Thrombocytopenia Patients With Malignant Tumor</brief_title>
	<detailed_description />
	<mesh_term>Thrombocytopenia</mesh_term>
	<mesh_term>Neoplasms</mesh_term>
	<mesh_term>Oprelvekin</mesh_term>
	<criteria>1. prescription explicitly give injection Baijieyi ; 2. confirm histopathological cytological examination malignant tumor chemotherapy ; 3. treatment : platelet count reach 75Ã—10^9/L treatment chemotherapy use Baijieyi ; prevention : patient chemotherapy begin preventive administration BaiJieyi , chemotherapy previous cycle ; 4. male female , age 1885 year ; 5 . The main research information require complete . 1. use platelet chemical biological product chemotherapy cycle use Baijieyi ; 2. use drug cause thrombocytopenia chemotherapy cycle use Baijieyi ; 3. bone marrow dysfunction bone marrow involvement ; 4 . There cause thrombocytopenia , aplastic anemia , acute leukemia , radiation sickness , immune thrombocytopenic purpura , hypersplenism , course use Baijieyi .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>85 Years</maximum_age>
	<verification_date>August 2016</verification_date>
</DOC>